A living WHO guideline on drugs to prevent covid-19
The first version of this living guideline focuses on evidence for hydroxychloroquine (HQ). Subsequent updates will cover other drugs being investigated for prevention of covid-19. The panel made a strong recommendation against use of HQ for individuals who do not have covid-19.
Source:
British Medical Journal
SPS commentary:
The linked systematic review and network meta-analysis (6 trials, n=6059) found that hydroxychloroquine had a small or no effect on mortality and admission to hospital (high certainty evidence). There was a small or no effect on laboratory confirmed SARS-CoV-2 infection (moderate certainty evidence) but probably increased adverse events leading to discontinuation (moderate certainty evidence). The panel judged that almost all people would not consider this drug worthwhile.